Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 17 de 17
Filter
1.
Ann Oncol ; 16(3): 466-72, 2005 Mar.
Article in English | MEDLINE | ID: mdl-15695500

ABSTRACT

BACKGROUND: This randomized study compared the efficacy and safety of fludarabine-mitoxantrone (FM) with mini-CHVP (cyclophosphamide, doxorubicin, vindesine, prednisone) in elderly patients with advanced, low-grade non-Hodgkin's lymphoma. PATIENTS AND METHODS: End points were remission rates [overall response (OR) and complete response (CR)], failure-free survival (FFS), survival and toxicity. One hundred and fifty-five patients were randomized, 144 were evaluable for safety and 142 for response. Each treatment arm was given as six monthly cycles, followed by three bimonthly cycles. FM comprised fludarabine (20 mg/m(2) i.v.), days 1-5, plus mitoxantrone (10 mg/m(2) i.v.), day 1. CHVP cycles comprised cyclophosphamide (750 mg/m(2) i.v. infusion), doxorubicin (25 mg/m(2) i.v.) and vindesine (3 mg/m(2) i.v.) on day 1, and prednisone (50 mg/m(2)) on days 1-5. RESULTS: FM therapy resulted in superior remission rates (OR 81% versus 64%, CR 49% versus 17%; P = 0.0004). Median FFS for FM patients was 36 months, compared with 19 months for CHVP patients, and has not yet been reached for early CR patients at 53 months. Treatment arm was the major risk factor influencing survival. Both treatments were well tolerated, with only few infectious complications. CONCLUSION: FM was more effective than CHVP in achieving OR and CR, and favorably affected the outcome.


Subject(s)
Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Lymphoma, Non-Hodgkin/drug therapy , Lymphoma, Non-Hodgkin/immunology , Vidarabine/analogs & derivatives , Age Factors , Aged , Cyclophosphamide/administration & dosage , Disease-Free Survival , Doxorubicin/administration & dosage , Female , Follow-Up Studies , Humans , Lymphoma, Non-Hodgkin/pathology , Male , Middle Aged , Mitoxantrone/administration & dosage , Prednisone/administration & dosage , Risk Factors , Vidarabine/administration & dosage , Vindesine/administration & dosage
2.
Leukemia ; 17(1): 45-51, 2003 Jan.
Article in English | MEDLINE | ID: mdl-12529659

ABSTRACT

With the introduction of new drugs such as alpha-interferon (IFN) and purine analogs, the management of hairy cell leukemia (HCL) patients has changed. However, deoxycoformycin (DCF) produced higher complete remission rates than IFN. The current study was undertaken to provide long-term data on duration of overall survival (OS) and disease-free survival (DFS) and incidence of subsequent malignancies. We retrospectively analyzed the data of patients treated with DCF (4 mg/m2/day, every 2 weeks) from 39 French centers. In 84 of 238 included patients, DCF was the first-line therapy. Pretreatment variables influencing the achievement of complete remission, DFS, and OS were identified by multivariate analysis. Two hundred and thirty-eight patients received a median of nine cycles (range, 1-19 cycles). A complete remission was obtained in 182 of 230 evaluable patients (79%) and a partial response was obtained in 38 patients, for an overall response rate of 95.6%. In the multivariate analysis hemoglobin level less than 100 g/l and leukocytes less than 2 x 10(9)/l were parameters adversely influencing complete remission achievement. With a median follow-up of 63.5 months (range, 0.39-138.4 months), disease recurrence was observed in 34 of 220 responding patients (15%). The estimated 5-years and 10-years DFS was 88.1% and 68.8%, respectively. Hemoglobin level less than 100 g/l and leukocytes less than 2 x 10(9)/l were the pre-treatment variables associated with a shorter DFS. The estimated 5-year and 10-year OS were 89.4% and 88.7%, respectively. Hemoglobin level less than 100 g/l, leukocytes less than 2 x 10(9)/l, and adenopathy were significant factors of reduced survival. Hematologic toxicity was the main side-effect, followed by infection and emesis. During the period of follow-up, 18 patients developed second cancer, but the standardized incidence ratio was 0.95. Pentostatin is a highly effective regimen for hairy cell leukemia that produces durable complete responses. Toxicity of DCF is acceptable. Subsequent malignancies do not appear to be increased with pentostatin treatment.


Subject(s)
Antibiotics, Antineoplastic/therapeutic use , Leukemia, Hairy Cell/drug therapy , Pentostatin/therapeutic use , Adult , Aged , Aged, 80 and over , Antibiotics, Antineoplastic/adverse effects , Disease-Free Survival , Female , Follow-Up Studies , France/epidemiology , Humans , Leukemia, Hairy Cell/epidemiology , Leukemia, Hairy Cell/pathology , Male , Middle Aged , Neoplasm Recurrence, Local/drug therapy , Neoplasm Recurrence, Local/pathology , Neoplasms, Second Primary , Pentostatin/adverse effects , Retrospective Studies , Survival Rate , Treatment Outcome
3.
Leukemia ; 15(11): 1785-91, 2001 Nov.
Article in English | MEDLINE | ID: mdl-11681422

ABSTRACT

The blastic variant (BV) form of mantle cell lymphoma (MCL) is considered to be a very aggressive subtype of non-Hodgkin's lymphoma (NHL). In order to determine its clinico-biological features and response to therapy we studied 33 patients (17%) out of 187 suffering from MCL who were diagnosed with a BV of MCL. Blastic variant was diagnosed according to histopathological patterns, immunophenotyping, and bcl1 gene rearrangement and/or cyclin D1 overexpression. Three patients initially diagnosed with large cell NHL were classified as BV. Patients received front-line therapy including CHOP-like regimen or CVP (n = 29), or chlorambucil (n = 4) and CHOP or ESAP as second-line therapy. High-dose intensification with stem cell transplantation (SCT) was performed in 11 cases (autoSCT, n = 8; alloSCT, n = 3). All but two patients were in complete remission (CR) at the time of transplant (CR1, n = 5; CR2, n = 4). Clinical and biological characteristics did not differ from those of the common form of MCL. The median age was 62 years (29-80), with a sex ratio (M/F) of 2.6:1. Of the 33 patients, 66% had extranodal site involvement, 85% had an Ann Arbor stage IV, and 82% had peripheral lymphadenopathy. Circulating lymphomatous cells were seen in 48% of cases. Twelve patients (36%) entered a CR1 with a median duration of 11 months. Fifteen patients (46%) failed to respond and rapidly died of progressive disease. Second-line therapy led to a 26% (6/23) CR2 rate. Nine patients relapsed after high-dose therapy. Twenty-two of the 33 patients (66%) died of refractory or progressive disease. Median overall survival (OS) time was 14.5 months for the 33 BV patients as compared to 53 months for the 154 patients with a common form of MCL, P <0.0001. In the univariate analysis, OS was influenced by age, extranodal site involvement, circulating lymphomatous cells, and international prognosis index (IPI). In the multivariate analysis, only IPI affected OS: patients with IPI > or =2 had 8 months median OS as compared to 36 months median OS for patients with IPI <2, P = 0.003. Blastic variant is one of the worst forms of NHL. An improved recognition of BV of MCL is required, particularly in high-grade CD5+ NHL using immunophenotyping and bcl1 molecular study. Standard therapy using anthracycline or even high-dose intensification produce poor results and an alternative treatment should be proposed to such patients.


Subject(s)
Lymphoma, Mantle-Cell/diagnosis , Lymphoma, Mantle-Cell/mortality , Adult , Aged , Disease-Free Survival , Female , Gene Rearrangement , Genes, bcl-1 , Humans , Immunophenotyping , Lymphoma, Mantle-Cell/therapy , Male , Middle Aged , Prognosis , Retrospective Studies , Survival Rate , Treatment Outcome
4.
Leukemia ; 14(1): 119-22, 2000 Jan.
Article in English | MEDLINE | ID: mdl-10637486

ABSTRACT

Jumping translocation (JT) is a very rare cytogenetic event, occurring especially in cancer. We describe a case of secondary acute monocytic leukemia (AML5b) with a JT involving the 3q13-3qter segment and leading to a partial trisomy 3. Each clone with JT was associated with trisomy 8 or tetrasomy 8. The literature of JT in AML cases is reviewed: only 13 cases of AML associated with JT have been previously described, seven of which are AML4/5 FAB subtype. Jumping translocation involvement in leukemogenesis is discussed. Leukemia (2000) 14, 119-122.


Subject(s)
Leukemia, Myelomonocytic, Acute/genetics , Translocation, Genetic , Adult , Aged , Female , Humans , Immunophenotyping , In Situ Hybridization, Fluorescence , Karyotyping , Leukemia, Myelomonocytic, Acute/drug therapy , Leukemia, Myelomonocytic, Acute/immunology , Male , Middle Aged
5.
Ann Oncol ; 9(2): 195-203, 1998 Feb.
Article in English | MEDLINE | ID: mdl-9553666

ABSTRACT

BACKGROUND: The treatment of Hodgkin's disease (HD) at advanced stages relies mainly upon multi-agent chemotherapies (CT), while the role of radiation therapy has not been definitely identified. The aim of this report is to analyze the 10-year results of a prospective study including 133 patients with HD clinical stages (CS) IIIA to IVB treated by three monthly courses of ABVD (adriamycin, bleomycin, vinblastin, and dacarbazine) followed by high-dose subtotal or total lymphoid irradiation [(S)TLI]. PATIENTS AND METHODS: From 1 October 1981 to 30 September 1988, 133 adult patients with HD CS IIIA (45), IIIB (33), IVA (seven) and IVB (48) were entered in the non-randomized multicentric prospective trial POF81/34. The number of involved nodal areas (NINA), and the number of visceral sites (NVIS) involved were registered in all patients; patients with bulky mediastinal tumor (BuMT) (mediastinal mass ratio > or = 0.45) were also identified. All patients received three monthly cycles of ABVD. Patients in complete remission (CR) or partial remission (PR) after completion of CT received a (S)TLI including the spleen (involved sites 40 Gy, non-involved 30 Gy); initially involved lung(s) and liver received 18 and 20 Gy, respectively; and patients not in CR or PR after CT or RT received salvage treatments. Univariate and multivariate analyses were performed to identify the factors contributing significantly to the prognosis; initial characteristics, as well as status after the three cycles of CT, were entered in the model. RESULTS: Of the 133 patients, 74 (55.6%) entered in CR after CT and 116 (87.2%) after completion of radiation therapy. Ten-year freedom from progression (FFP), freedom from tumor mortality (FFTM) and survival rates were 70.4%, 78.9% and 70.6%, respectively. According to univariate analysis the NVIS (< or = one vs. > or = two) was the only initial factor simultaneously influencing 10-year FFP (73.9% vs. 38.2%) FFTM (82.5 vs. 34.1%) and survival (73.5% vs. 17.3%) rates; on the other hand, the NINA (< or = four vs. > or = five) influenced FFP (81.4% vs. 60.7%) and FFTM rates (87.3% vs. 71.4%) while symptoms (A vs. B) influenced FFP (80.7% vs. 63.3%) and survival (82.8% vs, 61.2%) rates. Finally, age (< 40 vs. > or = 40) influenced survival rate only (79.2% vs. 50%). According to multivariate analysis, NVIS and NINA had an independent impact on FFP and FFTM, while survival was modified by the NVIS and age. The post-CT status (CR vs. no CR) had a major impact on FFP (85.3% vs. 64.9%) FFTM (92.1% vs. 63.3%) as well as on survival (78.6% vs. 54.7%) rates in both univariate and multivariate analyses. Complications of therapy were mainly due to RT: 11 patients acquired second malignancies, six developed lung fibrosis or severe pulmonary infections, three developed intestinal obstructions and six developed angina pectoris or carotid stenosis. CONCLUSIONS: Tumor burden (identified by the number of involved nodal areas and the number of visceral sites) and the response to initial CT were the two independent factors influencing the outcome of this group of 133 patients with HD, CSIII and IV treated by three cycles of ABVD followed by high-dose [(S)TLI].


Subject(s)
Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Hodgkin Disease/drug therapy , Hodgkin Disease/radiotherapy , Lymphatic Irradiation , Adult , Bleomycin/administration & dosage , Combined Modality Therapy , Dacarbazine/administration & dosage , Doxorubicin/administration & dosage , Female , Follow-Up Studies , Humans , Lymphatic Metastasis , Male , Multivariate Analysis , Prospective Studies , Survival Analysis , Vinblastine/administration & dosage
6.
Ann Oncol ; 8 Suppl 1: 49-52, 1997.
Article in English | MEDLINE | ID: mdl-9187429

ABSTRACT

BACKGROUND: The International Prognostic Index (IPI) is widely used to predict outcome of patients with aggressive lymphomas. Our goal was to assess the prognostic value of this index for low-grade lymphoma. PATIENTS AND METHODS: One hundred eighty-two patients with disseminated (stage III or IV) low-grade lymphoma were enrolled in a prospective multicenter trial. According to the initial features, treatment either was started immediately or was deferred until indicated by disease progression. Patients received the same polychemotherapy regimen, given monthly for six cycles. They were assigned to one of four risk groups according to the number of presenting risk factors: low-risk (0 or 1), low-intermediate-risk (2), high-intermediate-risk (3), high-risk groups (4). RESULTS: Survival curves (Kaplan-Meier method) demonstrated a high significant difference for the four groups (log-rank: P < 0.0001). Median survival for the low-risk group has yet to be reached, while that for the three other groups are, respectively, 65, 34, and 12 months. CONCLUSIONS: In this study, the IPI has been found to be an important prognostic tool in low-grade lymphoma and may be used in the selection of appropriate therapeutic approaches for individual patients.


Subject(s)
Lymphoma, Non-Hodgkin/mortality , Lymphoma, Non-Hodgkin/pathology , Severity of Illness Index , Humans , L-Lactate Dehydrogenase/blood , Lymphoma, Non-Hodgkin/therapy , Middle Aged , Neoplasm Staging , Predictive Value of Tests , Prognosis , Prospective Studies , Survival Analysis , Treatment Outcome
7.
J Clin Oncol ; 14(6): 1928-35, 1996 Jun.
Article in English | MEDLINE | ID: mdl-8656262

ABSTRACT

PURPOSE: To identify prognostic factors in 262 patients with supradiaphragmatic Hodgkin's disease (HD), clinical stages (CS) I and II, prospectively treated between 1981 and 1988 according to the Paris-Ouest-France (POF) 81/12 protocol by three 1-month cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine plus methylprednisone (ABVD-MP) followed by subtotal nodal irradiation (RT). PATIENTS AND METHODS: The size of mediastinal tumor (MT) was measured in all patients: 66 did not have MT (NoMT); 105 had a small-size MT (SSMT), ie, mediastinal mass ratio (MMR) less than 0.33; 58 had a medium-size MT (MSMT), ie, MMR > or = 0.33 and less than 0.45; and 33 had a bulky MT (BuMT), ie, MMR > or = 0.45. All patients received three cycles (CS IA, one cycle only) of ABVD-MP; patients in partial remission (PR) or complete remission (CR) after chemotherapy (CT) received supradiaphragmatic RT (involved fields, 40 Gy; adjacent fields, 30 Gy) plus lumboaortic and splenic RT (30 Gy); patients not in CR or PR after CT received salvage CT. RESULTS: Two hundred seventeen patients (82.8%) entered CR after CT and 258 (98.5%) after RT. Ten-year freedom-from-progression (FFP) and survival rateswere 88.6% and 89.4%, respectively. According to univariate analysis, MT size and post-CT status were the only factors to influence both FFP and survival. For patients with NoMT or SSMT, those with MSMT, and those with BuMT, FFP rates were 94.1%, 87.0%, and 63.0% (P < .001), respectively, while corresponding survival rates were 92.6%, 87.2%, and 78.2% (P < .05). FFP rates were significantly different between the patients who achieved CR and those who did not achieve CR after CT: 94.6% versus 65.3% (P < .001); corresponding survival rates were 89.9% and 73.7% (P < .01). Multivariate analysis confirmed that MT size and post-CT status were the only two prognostic factors for FFP; for survival, the same two characteristics, as well as age (< 40 v > or = 40 years), significantly affected prognosis. We were thus able to identify three groups. The 33 patients (12.6%) with a BuMT had 10-year FFP and survival rates of 63.0% and 78.2%, respectively. Of 229 patients without BuMT, the 195 who attained CR after CT had an optimal prognosis (FFP, 96.6%; survival, 93.6%), while those who failed to achieve CR after CT had an intermediate prognosis (FFP, 68.8%; survival, 77.6%). CONCLUSION: These results demonstrate the independent impact on HD prognosis of tumor burden and post-CT status.


Subject(s)
Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Hodgkin Disease/drug therapy , Mediastinal Neoplasms/drug therapy , Adolescent , Adult , Aged , Bleomycin/administration & dosage , Combined Modality Therapy , Dacarbazine/administration & dosage , Disease-Free Survival , Doxorubicin/administration & dosage , Female , Hodgkin Disease/mortality , Hodgkin Disease/pathology , Hodgkin Disease/radiotherapy , Humans , Male , Mediastinal Neoplasms/pathology , Mediastinal Neoplasms/radiotherapy , Methylprednisolone/administration & dosage , Middle Aged , Radiotherapy Dosage , Remission Induction , Survival Rate , Vinblastine/administration & dosage
8.
J Nucl Med ; 34(2): 182-6, 1993 Feb.
Article in English | MEDLINE | ID: mdl-8429334

ABSTRACT

We present a retrospective analysis of 111In-platelet sequestration studies in 111 patients with the clinical diagnosis of idiopathic thrombocytopenic purpura (ITP). Fifty-one of these patients underwent splenectomy, independent of the results of the 111In-platelet studies to determine if these isotopic results could accurately predict a beneficial response to splenectomy. Between January 1984 and June 1990, 111 patients who presented with ITP were subjected to a study of autologous 111In-labeled platelets through autotransfusion. The platelet sequestration site was splenic (81%), mixed (12%), or hepatic (7%). Fifty-one patients with persistent drug-resistant thrombocytopenia underwent splenectomy regardless of the isotopic results: 33 patients beyond 6 mo after diagnosis and 18 with high hemorrhagic risks before this delay. The follow-up median duration was 2.9 yr. Thirty-three of the 38 patients with splenic sequestration showed a normalized platelet count, as opposed to 2 of the 13 with mixed or hepatic sequestration (p < 0.001). In addition, platelet survival extended beyond 8 days in six patients, with no apparent sequestration site. The platelet isotopic study performed with this technique appears to be indicated in ITP: it guides clinicians in their decision to perform splenectomy and relates to a more central mechanism certain thrombocytopenias that are inappropriately categorized as ITP.


Subject(s)
Blood Platelets , Indium Radioisotopes , Purpura, Thrombocytopenic/diagnostic imaging , Purpura, Thrombocytopenic/surgery , Splenectomy , Adolescent , Adult , Aged , Female , Humans , Liver/diagnostic imaging , Male , Middle Aged , Radionuclide Imaging , Retrospective Studies , Spleen/diagnostic imaging
9.
Nouv Rev Fr Hematol (1978) ; 34(5): 399-403, 1992.
Article in English | MEDLINE | ID: mdl-1296193

ABSTRACT

An attempt was made to discover the aetiology of acquired portal vein thrombosis in 12 polycythaemic patients who did not show any obvious local or regional cause. In addition to the diagnostic criteria of polycythaemia vera, erythropoietin was determined and cultures of erythroblast precursors were examined. The patients could be divided into 3 groups, in the first of which the definite diagnosis of polycythaemia vera was made on the basis of the PVSG (Polycythaemia Vera Study Group) criteria and bone marrow biopsy (5 patients). In the second group (5 patients), there was a diagnosis of possible polycythaemia vera based essentially on the finding of a spontaneous growth of medullary CFU-E. Finally, diagnostic criteria for polycythaemia vera were absent in two patients. On the basis of these findings, the physiopathology of the association of portal thrombosis and polycythaemia is discussed, in particular polycythaemia secondary to hepatic ischaemia.


Subject(s)
Polycythemia Vera/complications , Portal Vein , Thrombosis/etiology , Adult , Blood Volume , Bone Marrow/pathology , Erythropoietin/blood , Female , Hematocrit , Humans , Iron Deficiencies , Male , Middle Aged , Polycythemia Vera/blood , Polycythemia Vera/diagnosis , Splenomegaly/etiology , Thrombosis/blood
10.
Ann Oncol ; 2(7): 485-7, 1991 Jul.
Article in English | MEDLINE | ID: mdl-1911455

ABSTRACT

Between May 1988 and November 1989, 68 consecutive febrile courses supervening after polychemotherapy for lymphoma outpatients (median age 50 years) were treated by the combination of oral Pefloxacin/Amoxicillin Clavulanic acid. In terms of median data, neutropenia appeared on d9 [d1-d17], and lasted 5 days [2-9] with a PMN nadir observed at 0.104 x 10(9) [0-0.5 x 10(9)/l], while fever rose on d10 [1-24]. In 59 cases (87%), fever and/or focal symptoms disappeared within 3 days, after which treatment was maintained for 7 days. Nine failures were observed, of which 2 were due to abandonment of treatment, 2 to vomiting and 5 to persistence of the original symptoms. Meti Susceptible-Staphylococci were found in blood samples from 2 patients, one of whom, with grade IV lymphoma that had proved resistant to chemotherapy, died. The treatment was found to be effective and well tolerated, offering a good alternative to hospitalization during a transient chemotherapy-induced neutropenia.


Subject(s)
Drug Therapy, Combination/therapeutic use , Neutropenia/drug therapy , Adolescent , Adult , Aged , Aged, 80 and over , Amoxicillin/administration & dosage , Anti-Bacterial Agents/administration & dosage , Antineoplastic Combined Chemotherapy Protocols/adverse effects , Clavulanic Acid , Clavulanic Acids/administration & dosage , Drug Administration Schedule , Female , Fever/drug therapy , Fever/etiology , Humans , Leukopenia/chemically induced , Lymphoma/complications , Lymphoma/drug therapy , Male , Middle Aged , Neutropenia/chemically induced , Pefloxacin/administration & dosage , Prospective Studies
11.
Ann Otol Rhinol Laryngol ; 99(7 Pt 1): 577-80, 1990 Jul.
Article in English | MEDLINE | ID: mdl-2195964

ABSTRACT

Laryngoscopy carried out in a 46-year-old man revealed a left paralaryngeal tumor. The mass was entirely removed by left pharyngolaryngotomy. Microscopic study showed a diffuse malignant lymphoma of low-grade malignancy, exhibiting all the criteria of the MALT-type lymphoma: the proliferation of centrocyte-like and lymphoplasmacytic cells, lymphoepithelial lesions, and the presence of germinal centers. Primary lymphoma of the larynx is a rare condition. Most of the reported low-grade lymphomas and the pseudolymphomas probably belong to the category of MALT-type lymphoma. Remission can be obtained by surgery, radiotherapy, and polychemotherapy.


Subject(s)
Glottis , Laryngeal Mucosa , Laryngeal Neoplasms/pathology , Larynx , Lymphoma/pathology , Plasmacytoma/pathology , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Combined Modality Therapy , Humans , Immunoenzyme Techniques , Laryngeal Neoplasms/therapy , Lymphoma/therapy , Male , Middle Aged , Plasmacytoma/therapy
12.
Nouv Rev Fr Hematol (1978) ; 32(4): 227-30, 1990.
Article in English | MEDLINE | ID: mdl-2290708

ABSTRACT

In order to reduce the incidence of severe complications noted with regimens containing high-dose cytarabine (HD ARA-C), wer used a combination of mitoxantrone (MTZ) in optimal dosage (12 mg/m2/day for 5 days) and cytarabine in intermediate dosage (1 g/m2 twice daily for 3 or 5 days). Thirty patients aged 2 to 65 years (median 51) with acute myeloid leukemia (AML), either refractory (8 patients), in first relapse (20 patients) or chemoinduced (2 patients), received this program. Seventeen (57%) achieved complete remission (CR). The main prognostic factor was the previous use of HD ARA-C (21% CR for patients previously treated with HD ARA-C versus 87% for patients treated with conventional doses: P less than 0.001). Mucositis was the most significant extrahematologic side-effect. There was no severe cerebellar toxicity. Two patients had transient congestive cardiac failure. This regimen is effective and relatively well tolerated in heavily pretreated patients. It can be used either as induction or consolidation therapy in AML.


Subject(s)
Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Leukemia, Myeloid, Acute/drug therapy , Mitoxantrone/administration & dosage , Adolescent , Adult , Aged , Antineoplastic Combined Chemotherapy Protocols/adverse effects , Child , Child, Preschool , Cytarabine/administration & dosage , Female , Humans , Male , Middle Aged , Prognosis , Recurrence , Remission Induction/methods
13.
Br J Haematol ; 60(1): 75-80, 1985 May.
Article in English | MEDLINE | ID: mdl-3873956

ABSTRACT

In order to assess the previously reported association of HLA-linked idiopathic haemochromatosis with idiopathic refractory sideroblastic anaemia (IRSA), the prevalence of HLA-A3 antigen in a group of 22 patients with IRSA was compared to that observed in healthy controls and in patients with homozygous idiopathic haemochromatosis and to that calculated for a population heterozygous for idiopathic haemochromatosis. The prevalence of A3 in patients with IRSA (0.23) was quite similar to that observed in controls (0.29) and significantly different from that observed in homozygous (0.73; P less than 10(-5] and heterozygous (0.57; P less than 10(-3] haemochromatosis. Serum iron, transferrin saturation, serum ferritin and liver iron concentration showed no difference in IRSA patients with or without A3. It is concluded that there is neither systematic association between the haemochromatosis allele and IRSA nor systematic implication of such an allele in the development of iron overload observed in IRSA.


Subject(s)
Anemia, Sideroblastic/immunology , HLA Antigens/analysis , Hemochromatosis/immunology , Aged , Alleles , Anemia, Sideroblastic/genetics , Anemia, Sideroblastic/metabolism , Female , HLA Antigens/genetics , HLA-A Antigens , HLA-A3 Antigen , HLA-B Antigens , Hemochromatosis/genetics , Hemochromatosis/metabolism , Humans , Iron/metabolism , Male , Middle Aged
14.
Acta Haematol ; 74(3): 137-43, 1985.
Article in English | MEDLINE | ID: mdl-3938157

ABSTRACT

In recent years we have had the occasion to observe hyperthyroidism in 6 patients with Hodgkin's disease. All patients had received Mantlefield irradiation and were disease-free when hyperthyroidism appeared. Hyperthyroidism allows three different pictures to be distinguished: 1 case report of Graves' disease without ophthalmopathy, 1 case report of Hashimoto's thyroiditis corresponding to a particular form called hashitoxicosis, and 4 case reports of atypical silent thyroiditis. Reports concerning case studies of postirradiation Graves' disease or Hashimoto's thyroiditis during Hodgkin's disease are only to be found exceptionally. Atypical silent thyroiditis was recently individualized, but no postirradiation case studies have been reported. It is suggested that these 6 cases represent a radiation-induced immune thyroid disease: physiopathology and predisposing factors are discussed.


Subject(s)
Hodgkin Disease/radiotherapy , Hyperthyroidism/etiology , Radiotherapy/adverse effects , Adult , Autoantibodies/immunology , Female , Humans , Male , Thyroid Gland/immunology , Thyroiditis, Autoimmune/etiology
16.
Nouv Rev Fr Hematol (1978) ; 23(4): 219-25, 1981.
Article in French | MEDLINE | ID: mdl-7312616

ABSTRACT

Histological changes in bone marrow reticulin were studied in 68 patients with adult acute leukaemia. Biopsies were performed on diagnosis and during the subsequent course of the disease. Marrow fibrosis was seen in 40% of the patients, with no predilection for morphological type of leukaemia. In most cases fibrosis was mild-to-moderate, diffuse, of the reticulin type and showing a fine regular fibre network. Pronounced fibrosis with signs of collagenization was rare. Complete regression of marrow fibrosis coincided with complete remission, and reappearance of fibrosis with relapse. The clinical and haematological course of acute leukaemia is not affected by marrow fibrosis, with the exception of more frequent bone pain and dry taps. Complete remission rate, remission induction time and mean survival time show little difference between patients with and without marrow fibrosis.


Subject(s)
Leukemia/complications , Primary Myelofibrosis/etiology , Acute Disease , Humans , Primary Myelofibrosis/pathology , Prognosis , Time Factors
17.
Sem Hop ; 55(19-20): 1003-7, 1979.
Article in French | MEDLINE | ID: mdl-227084

ABSTRACT

The authors report a new case of purpura due to an IgA (K) - IgG cryoglobulinemia, which is a rare immunological event. They recall the main clinical, etiological and therapeutic data of "essential mixed cryoglobulinemia" and compare this observation to other similar cases of the literature.


Subject(s)
Cryoglobulins , Immunoglobulin A , Immunoglobulin G , Paraproteinemias/complications , Purpura/etiology , Aged , Female , Humans , Paraproteinemias/immunology , Purpura/immunology
SELECTION OF CITATIONS
SEARCH DETAIL
...